A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion
Latest Information Update: 23 Dec 2021
At a glance
- Drugs Idelalisib (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms Havasu
- Sponsors Gilead Sciences
- 18 Dec 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 12 Dec 2017 Results (n=853) of ad hoc analysis assessing rates of grade more than or equal to 3 transaminase elevation using patient data from this and other 5 trials presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 25 Jun 2017 Results analysing safety of first-line idelalisib with rituximab in patients with B-cell chronic lymphocytic leukaemia with 17p deletion, presented at the 22nd Congress of the European Haematology Association.